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Investigating the role of HER3 in the
resistance to EGFR tyrosine kinase
inhibitors in non-small cell lung cancer
Margaret Larsen, Hui Lyu, Bolin Liu
LSUHSC-New Orleans, Stanley S. Scott Cancer Center, Departments of Interdisciplinary Oncology and Genetics

Introduction

Cell proliferation

Activation of downstream signaling

• Non-small cell lung cancer (NSCLC) comprises 80% of lung
cancer cases.
• NSCLC has a 5-year survival rate of approximately 19%.
• Epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) have shown promise in the treatment of NSCLC
patients with EGFR activating mutations.
• Patients frequently develop resistance to EGFR-TKIs
emphasizing the significance of studying the underlying
mechanism.

Figure 3. Western blot assays showing the levels of phosphorylated proteins for several
downstream signaling pathways of HER3 in resistant and parental NSCLC cell lines.
Phosphorylated HER3 (pHER3), ERK1/2 (pEKR1/2), and STAT3 (pSTAT3) are upregulated in
most of the resistant cell lines compared to the parental cell lines. b-actin is used as a loading
control.

• Human epidermal growth factor receptor 3 (HER3) is a
member of the EGFR family and is unique in that it has little to
no intrinsic tyrosine kinase activity.

mRNA expression changes

Hypothesis
We hypothesize that EGFR mutants (EGFRm) are working
conjunction with HER3 and other membrane receptors
continue activating the downstream signaling pathways
order to evade the effects of EGFR-TKIs, resulting
therapeutic resistance.
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Figure 1. MTS assays performed with NSCLC parental and EGFR-TKI resistant cell lines. Cell
proliferation (MTS) assays were used to determine the effect of osimertinib (3rd generation EGFRTKI) on both parental and EGFR-TKI resistant cell lines. A-B, EGFR-TKI resistant HCC827 and
PC9 cell lines (HCC827 AR, HCC827 ER, PC9 AR, PC9 GR/AR) are shown to maintain the
resistance phenotype even in increasing concentrations of osimertinib (AZD9291) compared to
parental cell lines. (**, p≤0.01; ***, p≤0.001)

Expression of membrane receptors

Methods

Figure 4. Quantitative reverse transcriptase polymerase chain reaction (RT-qPCR)
showing mRNA expression levels for several membrane proteins. PC9 (A) and HCC827
(B) resistant cell lines show statistically significant mRNA amplification of MET, while
transcriptional changes of EGFR and HER3 are variable between the two resistant cells lines
compared to the control. (*, p≤0.05; **, p≤0.01; ***, p≤0.001)

Conclusions
• Cell lines resistant to EGFR-TKIs maintain their resistance phenotype as
indicated by the MTS results.
• HER3 and MET overexpression is shown in several of the resistance cell
lines compared to the parental in both Western blots and RT-qPCR,
indicating possible involvement of these two receptors in EGFR-TKI
resistance.
Figure 2. Western blot assays showing the levels of protein expression of several membrane
receptors in resistant and parental NSCLC cell lines. Wild-type EGFR (WT EGFR) levels vary
among the cell lines, while mutant EGFR (EGFRm) levels remain relatively constant. Mesenchymalepithelial transition (MET) protein amplification is seen strongly with HCC827 resistant cell lines.
HER3 levels increase in PC9 resistant cell lines, while they stay the same or decrease in HCC827
resistant cell lines. b-actin is used as a loading control.

• Increased levels of p-STAT3 and p-ERK1/2 in resistance cell lines versus
control suggest continued activation of downstream signaling pathways as
a way to compromise the efficacy of EGFR-TKIs.
• Future studies will continue to define the role of HER3-mediated signaling
in the resistance to EGFR-TKIs in NSCLC.
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